Laura Steele

Laura Steele is a senior Eli Lilly and Company executive who has led U.S. commercial business units, including U.S. Cardiometabolic Health and U.S. Neuroscience. She previously served as President and General Manager for Lilly UK, Ireland and Northern Europe, overseeing commercial operations across diabetes, obesity, oncology, immunology and neuroscience portfolios.

GLP-1s Are Reshaping Consumer Spending and Employer Health Benefits

A panel at Aspen Ideas: Health argued that GLP-1 drugs are becoming an economic force well beyond pharmaceuticals, changing what households buy while forcing employers, insurers, public programs, pharmacy benefit managers and manufacturers to rethink access to expensive chronic-care medicines. PwC’s Ali Furman pointed to spending shifts in groceries, restaurants, apparel and travel; Eli Lilly’s Laura Steele described new direct-to-consumer and employer channels built around demand; and economist Kosali Simon cautioned that the benefits may not show up simply as lower medical costs.

The Aspen InstituteJun 24, 202619 min read